Variable | OR | 95Â % CI | P |
---|---|---|---|
Univariate regression | Â | ||
History congestive cardiac failure | 2.84 | 1.05–7.65 | 0.04 |
Peripheral vascular disease | 2.06 | 0.99–4.27 | 0.05 |
Cerebrovascular disease | 0.40 | 0.14–1.10 | 0.07 |
SIRS | 1.77 | 0.96–3.27 | 0.07 |
Ischaemic heart disease | 1.71 | 0.91–3.23 | 0.10 |
Mitral valve disease | 0.25 | 0.05–1.26 | 0.09 |
Metastatic tumour | 3.03 | 0.79–11.6 | 0.11 |
Leukaemia | 3.03 | 0.79-11.61 | 0.11 |
Age | 1.02 | 1.00–1.04 | 0.12 |
Body mass index | 0.96 | 0.92–1.00 | 0.06 |
Concurrent use of beta-blockers | 1.50 | 0.83-2.73 | 0.18 |
Concurrent use of digoxin* | 5.06 | 2.20–11.67 | <0.001 |
Ceasing amiodarone while on inotrope infusion | 8.76 | 3.58–21.4 | <0.001 |
Delay of infusion after bolus dose of amiodarone | 1.86 | 1.02–3.44 | 0.05 |
Receiving a bolus dose and infusion of amiodarone | 0.44 | 0.23–0.86 | 0.02 |
Remaining on amiodarone to discharge from ICU | 0.02 | 0.01–0.05 | <0.001 |
Multivariate regression | Â | ||
Ceasing amiodarone while on inotrope infusion | 5.89 | 1.86–18.6 | 0.003 |
Remaining on amiodarone for duration of ICU admission | 0.01 | 0.003–0.04 | <0.001 |
SIRS | 4.21 | 1.32–13.4 | 0.02 |
Hosmer and Lemeshow Goodness of Fit Chi2 7.19, P = 0.21 | |||
Area under ROC curve (discrimination) 0.92 |